Hypertension & Pulmonary Hypertension — Clinical Documentation Guide (2026)

🔍 Definition

Systemic hypertension (HTN) is a chronic medical condition defined as persistently elevated arterial blood pressure — classically ≥130/80 mmHg per the 2017 ACC/AHA Hypertension Guideline, and ≥140/90 mmHg per older JNC 7 criteria. In ICD-10-CM, there are no BP thresholds or severity descriptors (mild/moderate/severe) embedded in the code structure — the classification hinges entirely on documented causality, organ involvement, and complications. The FY2026 ICD-10-CM Official Guidelines section I.C.9 governs hypertension coding and its presumed causal relationships.

Pulmonary hypertension (PH) is a hemodynamic and pathophysiological state defined as a mean pulmonary arterial pressure (mPAP) >20 mmHg at rest, as updated by the 6th World Symposium on Pulmonary Hypertension (Nice, 2018). The older threshold was ≥25 mmHg. PH encompasses five WHO/Nice diagnostic groups with distinct etiologies, treatments, and ICD-10-CM codes. It is distinct from systemic hypertension and is coded in the I27.x category.

Clinical significance for coders and CDI specialists: Hypertension is the most common chronic condition documented in inpatient and outpatient records. Accurate coding — especially capturing hypertensive heart disease (I11.x), hypertensive CKD (I12.x), and the combination (I13.x) — is essential for proper DRG assignment, risk adjustment, quality measures, and HCC capture under CMS HCC Model v28.

🗂️ Alternative Terminology

🩺 Signs & Symptoms

Systemic Hypertension

Systemic hypertension is frequently asymptomatic and discovered incidentally. When symptomatic, common manifestations include:

• Headache — classically occipital, worse in the morning; may signal hypertensive urgency/emergency
• Epistaxis — nose bleeds associated with elevated BP
• Visual changes — blurred vision, scotoma in hypertensive retinopathy (H35.0, code I10 first)
• Dizziness / lightheadedness
• Palpitations / chest pain — especially with hypertensive heart disease
• Dyspnea — when hypertensive heart failure (I11.0) has developed
• Edema — peripheral or pulmonary when concurrent heart failure or CKD is present
• Hematuria, proteinuria — signs of hypertensive nephropathy (I12.x)
• End-organ damage signs in HTN emergency (I16.1): papilledema, focal neurological deficits, AKI (elevated creatinine), chest pain (AMI/aortic dissection), pulmonary edema

Pulmonary Hypertension

• Dyspnea on exertion — earliest and most common symptom; progresses to dyspnea at rest
• Fatigue and weakness
• Syncope or pre-syncope — exertional, indicates severe PH
• Chest pain — right ventricular angina, often exertional
• Peripheral edema — sign of right heart failure / cor pulmonale (I27.81)
• Cyanosis — in advanced or shunt-related PH (Eisenmenger syndrome I27.83)
• Loud P2 (pulmonary component of S2) on auscultation; right ventricular heave
• Hemoptysis — uncommon; occurs in CTEPH (I27.24) or idiopathic PAH
• Ascites / hepatomegaly — in advanced cor pulmonale with right ventricular failure

🧭 Differential Diagnosis

📋 Clinical Indicators for Coders/CDI

🦴 Anatomy & Pathophysiology

Systemic Hypertension

Essential hypertension results from a complex interplay of genetic predisposition and environmental factors that increase systemic vascular resistance (SVR). The renin-angiotensin-aldosterone system (RAAS) plays a central role — angiotensin II causes direct vasoconstriction and stimulates aldosterone release, increasing sodium and water retention. Sympathetic nervous system overactivation, endothelial dysfunction, and impaired nitric oxide bioavailability compound the elevated BP.

End-organ damage pathways:

• Heart: Pressure overload causes left ventricular hypertrophy (LVH) → diastolic dysfunction → heart failure with preserved EF (HFpEF). Chronic pressure overload may eventually cause systolic dysfunction (HFrEF). The coronary microcirculation also sustains injury, increasing ischemic risk.
• Kidneys: Hypertension causes glomerular hypertension, progressive nephrosclerosis, and podocyte damage → proteinuria → CKD. Per ICD-10-CM Guidelines I.C.9.a.2, the relationship between HTN and CKD is always assumed causal without explicit documentation.
• Brain: Small vessel disease, lacunar infarcts, cerebral microbleeds, and in HTN emergency, cerebral autoregulation failure → hypertensive encephalopathy (I67.4).
• Retina: Arteriovenous nicking, copper-wiring, flame hemorrhages, papilledema (grade IV) — coded as H35.0 with I10 as mandatory “code first” code.
• Aorta: Chronic pressure stress contributes to aortic dissection (I71.x) and aneurysm formation.

Pulmonary Hypertension

In PAH (Group 1), vasoconstriction, smooth muscle proliferation, endothelial dysfunction, and thrombosis in situ narrow the pulmonary arterioles, raising pulmonary vascular resistance (PVR). The right ventricle (RV) initially adapts via hypertrophy, but eventually fails — manifesting as cor pulmonale (I27.81). Key vasoactive imbalances: reduced prostacyclin (vasodilator), reduced nitric oxide, elevated endothelin-1 (potent vasoconstrictor and proliferative agent). Targeted PAH therapies address these pathways (endothelin receptor antagonists, PDE-5 inhibitors, prostacyclin analogues, soluble guanylate cyclase stimulators).

In Groups 2–5, the mechanism differs by etiology: Group 2 PH occurs from elevated pulmonary venous pressure transmitted backward from left-sided cardiac disease; Group 3 from chronic hypoxic vasoconstriction; Group 4 from mechanical obstruction of pulmonary vessels by organized thrombus; Group 5 from miscellaneous mechanisms including extrinsic compression or metabolic derangements.

💊 Medication Impact / Treatment

Antihypertensive Medication Classes (Systemic HTN)

Chronic antihypertensive pharmacotherapy should be documented in the medical record and may be flagged with long-term drug use code Z79.899 (Other long-term drug use). Key classes:

• ACE inhibitors / ARBs — first-line for HTN with CKD/proteinuria and hypertensive HF; renal-protective. E.g., lisinopril, enalapril (ACEi); losartan, valsartan (ARB). ARNI (sacubitril/valsartan) for HFrEF.
• Thiazide / thiazide-like diuretics — hydrochlorothiazide, chlorthalidone; first-line in many guidelines.
• Calcium channel blockers (CCB) — amlodipine; first-line; especially for older adults and isolated systolic HTN.
• Beta-blockers — metoprolol succinate, carvedilol; preferred with hypertensive heart disease/HF; atenolol for rate control.
• Aldosterone antagonists — spironolactone, eplerenone; used in resistant HTN and primary aldosteronism (I15.2).
• Loop diuretics — furosemide (J1940), bumetanide; for volume overload with HTN + HF or CKD stage 4-5.
• Alpha-1 blockers, central agonists (clonidine), direct vasodilators (hydralazine) — adjunctive.
• IV antihypertensives for HTN emergency — nicardipine, labetalol, clevidipine, esmolol, nitroprusside; coded per IV drug administration.
• Epoetin alfa in ESRD — Q4081 (HCPCS); secondary polycythemia can contribute to elevated BP.

PAH-Specific Therapies

PAH requires specialized treatments targeting the pathobiological pathways. Oral agents are generally covered under Medicare Part D; IV/SC/inhaled agents may be covered under Part B or DME:

• Endothelin receptor antagonists (ERAs) — bosentan (Tracleer), ambrisentan (Letairis), macitentan (Opsumit); oral — Part D. Require REMS programs due to hepatotoxicity/teratogenicity risk.
• PDE-5 inhibitors — sildenafil (Revatio), tadalafil (Adcirca); oral — Part D.
• Soluble guanylate cyclase (sGC) stimulators — riociguat (Adempas); oral — Part D. CONTRAINDICATED with PDE-5 inhibitors.
• Prostacyclin analogues / pathway agonists:
  • Epoprostenol (Flolan, Veletri) IV continuous — J3490 or billed under ambulatory infusion pump E0781; Part B DME pump
  • Treprostinil SC/IV (Remodulin) — J3490; inhaled (Tyvaso) — J3490 or Part B nebulizer
  • Iloprost inhaled (Ventavis) — J3490
• Selexipag (Uptravi) — oral prostacyclin receptor agonist; Part D.

Documentation of specific PAH therapy should prompt CDI review to ensure appropriate PAH group coding (I27.0, I27.21–I27.29) and confirmation that right heart catheterization values are captured in the record.

Preview ends here. The full guide continues with FY2026 ICD-10-CM code sets, CPT procedure coding, HCC v28 risk adjustment mapping, CDI query templates, MS-DRG impact, and a complete audit checklist — all available to CCO Members.

← Back to All Clinical Documentation Guides

📘 ICD-10-CM Guidelines (FY2026)

Guideline I.C.9.a — Hypertension

The FY2026 ICD-10-CM Official Guidelines for Coding and Reporting, Section I.C.9.a, provides the following rules for hypertension:

I.C.9.a.1 — Hypertension with Heart Disease

ICD-10-CM presumes a causal relationship between hypertension and heart failure or heart disease per the “with” convention (Guideline I.A.15). The index entry for “hypertension, with heart disease” includes heart failure, cardiomegaly, cardiac hypertrophy, and LVH. When these conditions are documented together, assign a combination code from I11.x. The physician must document the causal relationship explicitly — unlike hypertension + CKD, the heart disease/HF link requires physician documentation or index guidance to code the combination. Assign I11.0 when heart failure is documented, plus additional codes from I50.x to identify the type of heart failure. Assign I11.9 when no heart failure is present.

I.C.9.a.2 — Hypertensive Chronic Kidney Disease

The relationship between hypertension and CKD is always presumed causal per ICD-10-CM Guidelines, regardless of whether the provider documents the link. When a patient has both hypertension (any type) and CKD, assign a code from I12.x. Do NOT separately code I10 + N18.x — this is a coding error. Always assign the appropriate N18.x code as an additional code to indicate the CKD stage. CKD without hypertension uses N18.x alone. Hypertension without CKD uses I10.

I.C.9.a.3 — Hypertensive Heart and Chronic Kidney Disease

When a patient has hypertension, heart disease/heart failure, AND CKD simultaneously, assign the appropriate combination code from I13.x. This is required regardless of whether all three conditions are explicitly linked. Use additional codes for the type of heart failure (I50.x) and CKD stage (N18.x).

I.C.9.a.4 — Secondary Hypertension

Secondary hypertension codes (I15.x) are assigned when an identifiable underlying cause is documented. Two codes are required: I15.x for the secondary HTN and a code for the underlying cause (e.g., renal artery stenosis I70.1, primary hyperaldosteronism E26.0x, pheochromocytoma D35.0x, Cushing syndrome E24.x). The secondary HTN code is sequenced first unless the underlying cause is the principal reason for the encounter.

I.C.9.a.11 — Hypertensive Crisis

Hypertensive crisis codes were added in FY2018 (I16.x). I16.0 (HTN urgency) is used when BP is severely elevated without end-organ damage. I16.1 (HTN emergency) is used when BP is severely elevated WITH acute end-organ damage. If the documentation supports HTN emergency and a specific end-organ damage condition (e.g., acute MI I21.x, intracerebral hemorrhage I61.x, AKI N17.x), code the EOD as an additional code. Note: I16.1 does NOT replace the specific EOD code — both must be reported.

Guideline I.C.9.b — Atherosclerotic Coronary Artery Disease and Angina

When CAD coexists with HTN, code both separately unless the documentation explicitly links them as part of the same disease process. CAD uses I25.x; hypertension uses I10/I11.x as appropriate.

Pregnancy Hypertension — Guideline I.C.15

During pregnancy, childbirth, and the puerperium, hypertension conditions use codes from Chapter 15 (O00–O9A), NOT codes from Chapter 9 (I00–I99). Pre-existing hypertension complicating pregnancy uses O10.x (by type: essential, secondary, pre-existing heart disease, CKD). Gestational hypertension without proteinuria uses O13.x. Gestational hypertension with proteinuria (preeclampsia) uses O14.x. Eclampsia uses O15.x.

Pediatric and Neonatal Pulmonary Hypertension — Guideline I.C.16

Persistent pulmonary hypertension of the newborn (PPHN) is coded P29.3. This condition reflects failure of the normal circulatory transition at birth, with high pulmonary vascular resistance and right-to-left shunting. It is distinct from PAH in adults and does not use I27.x codes.

HTN Coding Algorithm

1. Elevated BP at visit, no HTN diagnosis: → R03.0 only; do not infer HTN diagnosis
2. HTN documented, no complications: → I10
3. HTN + documented heart disease/HF: → I11.0 (with HF) + I50.x type; or I11.9 (without HF)
4. HTN + CKD of any stage: → Presume causal → I12.x + N18.x stage (do not use I10 + N18.x)
5. HTN + HF + CKD: → I13.x + N18.x + I50.x
6. Secondary HTN with identifiable cause: → I15.x + underlying cause code
7. BP ≥180/120: → I16.0 (urgency, no EOD) or I16.1 (emergency, with EOD) + EOD codes
8. Pregnancy + HTN: → O10.x–O16.x (NOT I10)

🔢 ICD-10-CM Code Set (FY2026)

Systemic Hypertension — I10–I16

Pulmonary Hypertension — I27.x

Pregnancy-Related Hypertension Codes

Neonatal/Pediatric Codes

Frequently Associated Comorbidity Codes

🔎 Indexing

Key alphabetic index entries in ICD-10-CM FY2026 for hypertension and pulmonary hypertension:

🏥 CPT (2026)

The following CY2026 CPT codes are commonly associated with hypertension diagnosis, monitoring, and management, as well as pulmonary hypertension workup and treatment.

🧾 HCPCS (2026)

📚 AHA Coding Clinic (Recent Guidance)

The following guidance from the AHA Coding Clinic for ICD-10-CM/PCS is relevant to hypertension and pulmonary hypertension coding:

💰 HCC / Risk Adjustment (v28)

Under the CMS HCC Model v28 (fully implemented for 2026 risk scores), hypertension and pulmonary hypertension codes map as follows. This is critical for Medicare Advantage revenue integrity, value-based contract performance, and quality reporting.

✍️ CDI Query Templates

All queries below are formatted per ACDIS/AHIMA compliant query standards: non-leading, multiple choice, include clinical indicators, identify impact on coding. CDI specialists should use these templates as frameworks, customizing with patient-specific clinical indicators.

🧑‍⚕️ Treatments (Clinical)

Systemic Hypertension — Treatment Overview

Hypertension treatment follows a stepwise approach per the AHA/ACC 2017 Hypertension Guidelines:

1. Lifestyle modification (first-line for all stages): DASH diet, sodium restriction (<2.3 g/day), weight loss, increased physical activity, moderation of alcohol, smoking cessation. Addresses F17.2xx, E66.x, and E11.x comorbidities.
2. Stage 1 HTN (130–139/80–89 mmHg with high CVD risk, or Stage 2 ≥140/90): Pharmacotherapy initiated. First-line agents: thiazide diuretics, CCBs, ACE inhibitors, ARBs — choice guided by compelling indications (CKD → ACEi/ARB; HF → beta-blocker, ACEi/ARB, aldosterone antagonist; diabetes → ACEi/ARB).
3. Resistant hypertension (BP uncontrolled on ≥3 agents including diuretic): Evaluate for secondary HTN (I15.x). Add mineralocorticoid receptor antagonist (spironolactone). Consider renal denervation (investigational).
4. Hypertensive urgency (I16.0): Outpatient oral agent dose adjustment; BP goal is gradual reduction over 24–48 hours; avoid rapid reduction (risk of ischemic events). Oral labetalol, amlodipine, or clonidine commonly used.
5. Hypertensive emergency (I16.1): ICU admission; IV antihypertensives (nicardipine, labetalol, clevidipine, nitroprusside, esmolol depending on end-organ damage type); goal: reduce MAP by ≤25% in first hour, then gradual normalization. Aortic dissection → esmolol + nitroprusside; ischemic stroke → permissive HTN until tPA threshold met; AKI/encephalopathy → nicardipine or labetalol.

Pulmonary Arterial Hypertension — Clinical Treatment

PAH treatment is risk-stratified per Nice 2018 PAH guidelines using low/intermediate/high risk classification based on WHO functional class, 6-minute walk distance, BNP/NT-proBNP, cardiac imaging, and RHC hemodynamics:

• Low-risk (WHO FC I-II, stable): Oral combination therapy — ERA + PDE-5 inhibitor (e.g., ambrisentan + tadalafil, per AMBITION trial).
• Intermediate-risk (WHO FC II-III): Oral triple therapy (ERA + PDE-5i + oral prostacyclin receptor agonist [selexipag]); consider transition to parenteral prostacyclin.
• High-risk (WHO FC III-IV, rapidly deteriorating): IV prostacyclin (epoprostenol, treprostinil) is preferred; IV epoprostenol has the strongest mortality evidence. Bridge to lung transplantation evaluation.
• Vasodilator-reactive PAH (Group 1): Calcium channel blockers (diltiazem, nifedipine, amlodipine) — ONLY for patients who test positive on acute vasodilator challenge during RHC (minority of IPAH patients).
• CTEPH (Group 4): Pulmonary endarterectomy (PEA) surgery is the treatment of choice for operable disease; riociguat (Adempas) is approved for inoperable CTEPH; balloon pulmonary angioplasty (BPA) is an emerging option. Lifelong anticoagulation required.
• Group 2 PH (left heart disease): Treat the underlying cardiac condition (HF, valvular disease). PAH-targeted therapies are generally NOT used and may be harmful in Group 2 PH.
• Group 3 PH (lung disease/hypoxia): Optimize lung disease treatment; supplemental oxygen; inhaled treprostinil (Tyvaso DPI) approved for PH-ILD (specific indication per FDA 2021 approval).
• Lung transplantation: For refractory PAH (Group 1) or CTEPH not amenable to PEA; bilateral lung or heart-lung transplant depending on cardiac involvement. Document evaluation and listing status in record (Z79.3 series or Z94.2 if post-transplant).

🎓 Patient Education / Summary

The following summary is designed for patient-facing use or for coding/CDI staff to communicate clinical context to documentation improvement initiatives.

What is Hypertension?

High blood pressure (hypertension) occurs when the force of blood pushing against artery walls is consistently too high. According to the American Heart Association, blood pressure is measured in two numbers: systolic (when the heart beats) over diastolic (when the heart rests). Normal is below 120/80 mmHg. Blood pressure at or above 130/80 mmHg in adults is classified as hypertension.

Why it matters for health: If left uncontrolled, high blood pressure damages blood vessels, the heart, kidneys, brain, and eyes over time. It is often called the “silent killer” because most people with hypertension have no symptoms. Regular monitoring and treatment are essential.

What is Pulmonary Hypertension?

Pulmonary hypertension (PH) is high blood pressure specifically in the lungs’ arteries. It is different from regular (systemic) hypertension. PH forces the right side of the heart to work harder to pump blood through the lungs, eventually leading to right heart failure (cor pulmonale) if untreated. Symptoms include worsening shortness of breath, fatigue, dizziness, and leg swelling. The Pulmonary Hypertension Association (PHA) is a patient resource for diagnosis, treatment, and support.

Key Lifestyle Recommendations (per AHA/ACC Guidelines)

• DASH diet — rich in fruits, vegetables, whole grains, low-fat dairy; limits sodium, saturated fat, red meat
• Limit sodium — target <2,300 mg/day (ideally <1,500 mg for HTN patients per DASH-Sodium trial)
• Regular exercise — 150 min/week moderate-intensity aerobic activity lowers BP by 5–8 mmHg
• Weight management — each kg of weight loss reduces BP ~1 mmHg
• Limit alcohol — ≤1 drink/day women, ≤2 drinks/day men
• Quit smoking — tobacco cessation reduces cardiovascular and renal risk (F17.2xx)
• Medication adherence — do not discontinue antihypertensives without physician guidance; rebound HTN can occur
• Home BP monitoring — log readings; typical target <130/80 mmHg at home for most adults per AHA 2017

CDI/Coder Quick Reference Summary

• I10 alone has NO HCC v28 — capture complications (I11.x, I12.x, I13.x) with full specificity
• HTN + CKD always → I12.x + N18.x (never I10 + N18.x)
• HTN + HF → I11.0 + I50.x type (physician link required)
• HTN + HF + CKD → I13.x + N18.x + I50.x
• PH Group coding → I27.0–I27.29 (not just I27.20) — query for group
• Cor pulmonale (I27.81) = HCC 223 (~0.359 RAF) — highest PH-related HCC
• PAH IV therapies (epoprostenol, treprostinil, iloprost) → J3490 / DME E0781
• Pregnancy HTN → always O10.x–O16.x, never I10 during pregnancy
• PPHN in newborns → P29.3 (not I27.x)

About this Guide

This Clinical Documentation Guide is published by CCO Academy and is intended for credentialed coding, CDI, and clinical documentation professionals. Content is updated for FY2026 ICD-10-CM (effective October 1, 2025). All code assignments should be verified against the official ICD-10-CM Tabular List, AHA Coding Clinic, and applicable payer-specific policies. This guide does not constitute legal, medical, or compliance advice.

Last reviewed: April 2026 · Next scheduled review: October 2026 (FY2027 update)